A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale

Journal of Clinical Epidemiology

Volumn 57, Issue 9, 2004, Pages 898-910

  Eton, David T ^a   Cella, David ^a   Yost, Kathleen J ^a   Yount, Susan E ^a   Peterman, Amy H ^a   Neuberg, Donna S ^b   Sledge, George W ^c   Wood, William C ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Breast cancer; Clinical significance; Functional Assessment of Cancer Therapy Breast questionnaire; health related; Minimal important difference; Quality of life

Indexed keywords

ADULT; AGED; ANALYTICAL ERROR; ARTICLE; BREAST CANCER; CANCER PAIN; CANCER THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DEMOGRAPHY; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; OUTCOMES RESEARCH; PERFORMANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; STANDARD; STATISTICAL SIGNIFICANCE; TECHNIQUE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; EPIDEMIOLOGIC METHODS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PAIN MEASUREMENT; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 7044224362     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2004.01.012     Document Type: Article

References (44)

1. American Cancer Society Cancer facts and figures, 2003 2003 ACS Atlanta (GA)
2. C.M. Saunders Current management of breast cancer Br J Hosp Med 50 1993 588 590
3. H.J. Burstein, and E.P. Winer Primary care for survivors of breast cancer N Engl J Med 343 2000 1086 1094
4. L. Jardines, B.G. Haffty, and R.L. Theriault Locally advanced, locally recurrent, and metastatic breast cancer R. Pazdur L.R. Coia W.J. Hoskins L.D. Wagman Cancer management: a multidisciplinary approach 1998 PRR Huntington, NY 49 63
5. D. Osoba, D. Slamon, M. Burchmore, and M. Murphy Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer J Clin Oncol 20 2002 3106 3113
6. A. Coates, V. Gebski, J.F. Bishop, P.N. Jeal, R.L. Woods, R. Snyder, M.H. Tattersall, M. Byrne, V. Harvey, and G. Gill Improving the quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment strategies N Engl J Med 317 1987 1490 1495
7. D.F. Cella, and D.S. Tulsky Quality of life in cancer: definition, purpose, and method of measurement Cancer Invest 11 1993 327 336
8. B.E. Meyerowitz Psychosocial correlates of breast cancer and its treatments Psychol Bull 87 1980 108 131
9. K. Glanz, and C. Lerman Psychosocial impact of breast cancer: a critical review Ann Behav Med 14 1992 204 212
10. A. Moyer, and P. Salovey Psychosocial sequelae of breast cancer and its treatment Ann Behav Med 18 1996 110 125
11. P.A. Ganz, C.A. Schag, and H.L. Cheng Assessing the quality of life: a study in newly-diagnosed breast cancer patients J Clin Epidemiol 43 1990 75 86
12. M.J. Brady, D.F. Cella, F. Mo, A.E. Bonomi, D.S. Tulsky, S.R. Lloyd, S. Deasy, M. Cobleigh, and G. Shiomoto Reliability and validity of the Functional Assessment of Cancer Therapy - Breast quality-of-life instrument J Clin Oncol 15 1997 974 986
13. P.A. Ganz, C.M. Moinpour, D.F. Cella, and J.H. Fetting Quality-of-life assessment in cancer clinical trials: a status report [Editorial] J Natl Cancer Inst 84 1992 994 995
14. American Society of Clinical Oncology Outcomes of cancer treatment for technology assessment and cancer treatment guidelines J Clin Oncol 14 1996 671 679
15. J. Johnson, and R. Temple Food and Drug Administration requirements for approval of new anticancer drugs Cancer Treat Rep 69 1985 1155 1159
16. S. Hirschfeld, and R. Pazdur Oncology drug development: United States Food and Drug Administration perspective Crit Rev Oncol Hematol 42 2002 137 143
17. K.H. Dow, B.R. Ferrell, S. Leigh, J. Ly, and P. Gulasekaram An evaluation of the quality of life among long-term survivors of breast cancer Breast Cancer Res Treat 39 1996 261 273
18. K. Ashing-Giwa, P.A. Ganz, and L. Petersen Quality of life of African-American and white long term breast carcinoma survivors Cancer 85 1999 418 426 [erratum:Cancer 1999;86:732-3.]
19. D.G. Tate, B.B. Riley, R. Perna, and S. Roller Quality of life issues among women with physical disabilities or breast cancer Arch Phys Med Rehabil 78 12 Suppl 5 1997 S18 S25
20. M.T. King, P. Kenny, A. Shiell, J. Hall, and J. Boyages Quality of life three months and one year after first treatment for early stage breast cancer: influence of treatment and patient characteristics Qual Life Res 9 2000 789 800
21. D. Osoba, G. Rodrigues, J. Myles, B. Zee, and J. Pater Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 1998 139 144
22. M.A. Sprangers, M. Groenvold, J.I. Arraras, J. Franklin, A. ten Velde, M. Muller, L. Franzini, A. Williams, H.C. de Haes, P. Hopwood, A. Cull, and N.K. Aaronson The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study J Clin Oncol 14 1996 2756 2768
23. J.A. Sloan, D. Cella, M. Frost, G.H. Guyatt, M. Sprangers, and T. Symonds Clinical Significance Consensus Meeting Group. Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms Mayo Clin Proc 77 2002 367 370
24. G.H. Guyatt, D. Osoba, A.W. Wu, K.W. Wyrwich, and G.R. Norman Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures Mayo Clin Proc 77 2002 371 383
25. D. Cella, M. Bullinger, C. Scott, and I. Barofsky Clinical Significance Consensus Meeting Group. Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life Mayo Clin Proc 77 2002 384 392
26. J.A. Sloan, N. Aaronson, J.C. Cappelleri, D.L. Fairclough, and C. Varricchio Clinical Significance Consensus Meeting Group. Assessing the clinical significance of single items relative to summated scores Mayo Clin Proc 77 2002 479 487
27. M.H. Frost, A.E. Bonomi, C.E. Ferrans, G.Y. Wong, and R.D. Hays Clinical Significance Consensus Meeting Group. Patient, clinician, and population perspectives on determining the clinical significance of quality-of-life scores Mayo Clin Proc 77 2002 488 494
28. M.A. Sprangers, C.M. Moinpour, T.J. Moynihan, D.L. Patrick, and D.A. Revicki Clinical Significance Consensus Meeting Group. Assessing meaningful change in quality of life over time: a users' guide for clinicians Mayo Clin Proc 77 2002 561 571
29. T. Symonds, R. Berzon, P. Marquis, and T.A. Rummans Clinical Significance Consensus Meeting Group. The clinical significance of quality-of-life results: practical considerations for specific audiences Mayo Clin Proc 77 2002 572 583
30. E. Lydick, and R. Epstein Interpretation of quality of life changes Qual Life Res 2 1993 221 226
31. K. Wyrwich, W. Tierney, and F. Wolinsky Further evidence supporting a SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life J Clin Epidemiol 52 1999 861 873
32. D. Cella, D.T. Eton, D.L. Fairclough, P. Bonomi, A.E. Heyes, C. Silberman, M.K. Wolf, and D.H. Johnson What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L)? Results from the Eastern Cooperative Oncology Group (ECOG) Study 5592 J Clin Epidemiol 55 2002 285 295
33. D. Cella, D.T. Eton, J.S. Lai, A. Peterman, and D.E. Merkel Combining anchor and distribution based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue scales J Pain Symptom Manage 24 2002 547 561
34. G. Sledge, D. Neuberg, P. Bernardo, J. Ingle, S. Martino, E. Rowinsky, and W. Wood Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 2003 588 592
35. C.G. Zubrod, M. Schneiderman, E. Frei III, C. Brindley, G.L. Gold, B. Shnider, R. Oviedo, J. Gorman, R. Jones, U. Jonsson, J. Colsky, T. Chalmers, B. Ferguson, M. Dederick, J. Holland, O. Selawry, W. Regelson, L. Lasagna, and A.H. Owens Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide J Chron Dis 11 1960 7 33
36. C.S. Cleeland Measurement of pain by subjective report C.R. Chapman J.D. Loeser Issues in pain measurement. Advances in Pain Research and Therapy Vol.. 12 1989 Raven Press New York 391 403
37. S.L. Du Pen, A.R. Du Pen, N. Polissar, J. Hansberry, B.M. Kraybill, M. Stillman, J. Panke, R. Everly, and K. Syrjala Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial J Clin Oncol 17 1999 361 370
38. M. Palangio, D.W. Northfelt, R.K. Portenoy, D. Brookoff, R.T. Doyle Jr., B.E. Dornseif, and M.C. Damask Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain J Pain Symptom Manage 23 2002 355 368
39. R.C. Serlin, T.R. Mendoza, Y. Nakamura, K.R. Edwards, and C.S. Cleeland When is cancer pain mild, moderate, or severe? Grading pain severity by its interference with function Pain 61 1995 277 284
40. D. Cella, A.E. Bonomi, S.R. Lloyd, D.S. Tulsky, E. Kaplan, and P. Bonomi Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument Lung Cancer 12 1995 199 220
41. P. Bonomi, K. Kim, D.L. Fairclough, D. Cella, J. Kugler, E. Rowinsky, M. Jiroutek, and D. Johnson Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial J Clin Oncol 18 2000 623 631
42. J. Cohen Statistical power analysis for the behavioral sciences 2nd edition 1988 Lawrence Erlbaum Hillsdale (NJ)
43. G.R. Norman, J.A. Sloan, and K.W. Wyrwich Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation Med Care 41 2003 582 592
44. P. Goodwin, J. Black, L. Bordeleau, and P. Ganz Health-related quality-of-life measurement in randomized clinical trials in breast cancer: taking stock J Natl Cancer Inst 95 2003 263 281